<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39341400</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.</ArticleTitle><Pagination><StartPage>106287</StartPage><MedlinePgn>106287</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2024.106287</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(24)00221-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to evaluate the impact of the pandemic and post-pandemic periods on hospital admissions for LRTI, with a focus on patients with chronic respiratory disease (CRD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From July 2013 to June 2023, monthly numbers of adult hospitalisations for LRTI (excluding SARS-CoV-2) were extracted from the French National Hospital Discharge Database. They were modelled by regressions with autocorrelated errors. Three periods were defined: (1) early pandemic and successive lockdowns; (2) gradual lifting of restrictions and widespread SARS-CoV-2 vaccination; (3) withdrawal of restriction measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pre-pandemic incidence was 96 (90.5 to 101.5) per 100,000 population. Compared with the pre-pandemic period, no more seasonality and significant reductions were estimated in the first two periods: -43.64% (-50.11 to -37.17) and -32.97% (-39.88 to -26.05), respectively. A rebound with a positive trend and a seasonal pattern was observed in period 3. Similar results were observed for CRD patients with no significant difference with pre-pandemic levels in the last period (-9.21%; -20.9% to 1.67%), albeit with differential changes according to the type of CRD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 pandemic containment measures contributed to changes in LRTI incidence, with a rapid increase and return to a seasonal pattern after their lifting, particularly in patients with CRD.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabaté-Elabbadi</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France; Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials Evasion (EMAE), Paris, France. Electronic address: alexandre.elabbadi@pasteur.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brolon</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France; Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials Evasion (EMAE), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brun-Buisson</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France; Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials Evasion (EMAE), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemot</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France; Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials Evasion (EMAE), Paris, France; Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris (AP-HP), Public Health, Medical Information, Clinical Research, Le Kremlin-Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fartoukh</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watier</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France; Institut Pasteur, Université Paris-Cité, Epidemiology and Modelling of Antimicrobials Evasion (EMAE), Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic respiratory disease</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">French National Hospital Discharge Database</Keyword><Keyword MajorTopicYN="N">Lower respiratory tract infection</Keyword><Keyword MajorTopicYN="N">Nationwide study</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alexandre Sabaté-Elabbadi reports support for attending meeting from SOS Oxygène and LVL Medical outside the submitted work. Muriel Fartoukh reports grants from BioMérieux and personal fees from BioMérieux, Pfizer, SOS Oxygène and Fisher and Paykel outside the submitted work. Laurence Watier reports personal fees from Pfizer, Sanofi and Heva outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39341400</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2024.106287</ArticleId><ArticleId IdType="pii">S0163-4453(24)00221-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>